Table 1.
Pathological and clinical characteristics of the study group regarding immunohistochemistry-based hormonal receptor status. Nominal variables are presented as raw values followed by percentages of the eligible groups, and continuous variables are presented as medians and interquartile ranges in brackets.
| Variable | Whole Group n = 353 (100) |
ER−PR− n = 34 (9.6) |
ER+PR− n = 73 (20.7) |
ER+PR+ n = 246 (69.7) |
p-Value |
|---|---|---|---|---|---|
| Age (years) 1 | 63.8 | 63.6 | 64.7 | 63.6 | 0.132 |
| (55.0–71.3) | (55.7–73.1) | (60.0–70.6) | (52.7–70.8) | ||
| Menopausal status 2 | 0.063 | ||||
| Pre | 37 (11.4) | 2 (6.1) | 3 (4.6) | 32 (14.1) | |
| Post | 288 (88.6) | 31 (93.9) | 62 (95.4) | 195 (85.9) | |
| Grade 2 | <0.001 * | ||||
| 1 | 42 (11.9) | 2 (5.9) | 9 (12.3) | 31 (12.6) | |
| 2 | 227 (64.3) | 12 (35.3) | 43 (58.9) | 168 (69.9) | |
| 3 | 84 (23.8) | 20 (58.8) | 21 (28.8) | 42 (17.5) | |
| Ki67 (%) 1 | 18.0 | 32.0 | 20.0 | 12.0 | 0.011 * |
| (5.0–30.0) | (30.5–35.5) | (10.0–40.0) | (5.0–25.0) | ||
| HER2 amplification positivity 2 | 45 (12.7) | 12 (35.3) | 13 (17.8) | 20.0 (8.1) | <0.001 * |
| Tumor size (mm) 1 | 20.0 | 25.0 | 25.0 | 20.0 | 0.004 * |
| (15.0–27.0) | (15.0–35.0) | (19.0–30.0) | (15.0–25.0) | ||
| T feature 2 | 0.064 | ||||
| pT1 | 143 (53.0) | 13 (40.6) | 15 (38.5) | 115 (57.8) | |
| pT2 | 116 (43.0) | 16 (50.0) | 22 (56.4) | 78 (39.2) | |
| pT3-4 | 11 (4.0) | 3 (9.4) | 2 (5.1) | 6 (3.0) | |
| Metastases present 2 | 116 (33.5) | 13 (42.4) | 25 (34.7) | 77 (32.0) | 0.475 |
| N feature 2 | 0.733 | ||||
| pN0 | 230 (66.5) | 17 (57.6) | 47 (65.3) | 164 (68.0) | |
| pN1 | 81 (23.4) | 10 (30.3) | 16 (22.2) | 55 (22.8) | |
| pN2-3 | 34 (10.1) | 4 (12.1) | 9 (12.5) | 22 (9.1) | |
| Staging 2 | 0.289 | ||||
| Very early (IA) | 135 (39.1) | 11 (34.4) | 23 (31.9) | 101 (41.9) | |
| Early (IB-IIIA) | 189 (54.8) | 17 (53.1) | 45 (62.5) | 127 (52.7) | |
| Advanced (IIIB-IV) | 21 (6.1) | 4 (12.5) | 4 (5.6) | 13 (5.4) | |
| Multifocality 2 | 39 (14.3) | 3 (8.8) | 6 (15.4) | 30 (15.0) | 0.622 |
| DCIS present 2 | 103 (29.1) | 10 (29.4) | 23 (31.5) | 70 (28.3) | 0.871 |
| Hormonotherapy 2 | 220 (81.2) | 0 (0.0) | 46 (82.1) | 174 (86.6) | <0.001 * |
| Neoadjuvant therapy 2 | 231 (75.5) | 26 (89.7) | 30 (48.4) | 175 (81.4) | <0.001 * |
| Adjuvant chemotherapy 2 | 150 (62.2) | 25 (80.7) | 38 (66.7) | 87 (56.9) | 0.032 * |
| Adjuvant radiotherapy 2 | 151 (64.8) | 11 (50.0) | 30 (61.2) | 110 (67.9) | 0.111 |
| Progression/relapse 3 | 30 (9.8) | 10 (31.3) | 8 (11.9) | 12 (5.8) | <0.001 * |
| Disease-free survival (years) | 3.9 (2.7–6.4) | 3.6 (2.2–4.5) | 3.8 (2.5–4.9) | 4.2 (2.9–6.6) | |
| Deaths 3 | 41 (11.6) | 10 (29.4) | 6 (8.2) | 25 (10.1) | <0.001 * |
| Overall survival (years) | 4.2 (2.9–6.5) | 3.6 (2.6–4.5) | 4.0 (2.7–5.5) | 4.7 (3.0–6.7) |
1 Kruskal–Wallis ANOVA test, 2 Pearson’s chi-squared test, 3 log-rank test, * significant differences.